---
title: "OTG Acquisition I - Unit | 10-Q: FY2025 Q2 Revenue: USD 0"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262684930.md"
published_at: "2025-10-24T20:32:22.000Z"
---

# OTG Acquisition I - Unit | 10-Q: FY2025 Q2 Revenue: USD 0

Revenue: As of FY2025 Q2, the actual value is USD 0.

EPS: As of FY2025 Q2, the actual value is USD 0.

EBIT: As of FY2025 Q2, the actual value is USD -14.51 K.

### Segment Revenue

-   The company has not commenced any operations and has not generated any operating revenues as of June 30, 2025. The company will generate non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering.

### Operational Metrics

-   **Net Loss**: The company reported a net loss of - $14,514 for the period from June 12, 2025 (inception) through June 30, 2025.
-   **General and Administrative Costs**: These costs amounted to $14,514 for the same period.

### Cash Flow

-   **Net Cash Used in Operating Activities**: The company reported no net cash used in operating activities for the period from June 12, 2025 (inception) through June 30, 2025.

### Unique Metrics

-   **Deferred Offering Costs**: The company reported deferred offering costs of $117,411 as of June 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company intends to effectuate its Business Combination using cash derived from the proceeds of the Initial Public Offering and the sale of the Private Placement Units, shares, debt, or a combination thereof.
-   **Non-Core Business**: The company has not selected any specific Business Combination target and has not engaged in any substantive discussions with any Business Combination target.
-   **Priority**: The company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account.

### Related Stocks

- [OTGAU.US - OTG Acquisition I - Unit](https://longbridge.com/en/quote/OTGAU.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GLP-1 drugs may cause scurvy in patients | GLP-1 weight loss drugs, including Ozempic and Wegovy, are linked to cases of scurvy, a rare illness caused by vitamin C | [Link](https://longbridge.com/en/news/275772745.md) |
| Smurfit Westrock Sets Bold 2030 Targets After Record Year | Smurfit Westrock PLC reported record adjusted EBITDA of USD 4.939 billion for FY2025, highlighting strong cash generatio | [Link](https://longbridge.com/en/news/276017547.md) |
| Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions | Alnylam Pharmaceuticals (ALNY) faces significant execution risks as it seeks to expand globally and achieve its 2030 gro | [Link](https://longbridge.com/en/news/275858709.md) |
| 10:15 ETMicronized PTFE Market worth $0.39 billion by 2030 - Exclusive Report by MarketsandMarkets™ | The micronized PTFE market is projected to grow from USD 0.30 billion in 2025 to USD 0.39 billion by 2030, at a CAGR of  | [Link](https://longbridge.com/en/news/275481023.md) |
| Smurfit Westrock CFO: 2030 growth targets not built on major rebound in demand | Smurfit Westrock PLC's CFO stated that the company's growth targets for 2030, aiming for $7 billion in FY EBITDA, are ba | [Link](https://longbridge.com/en/news/275630739.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.